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Bone resorption is a major pathological factor 
in chronic inflammatory diseases such as rheu-
matoid arthritis (RA), periodontitis, and osteo-
porosis. Osteoporosis is a disorder of impaired 
bone strength that causes skeletal fragility and 
increases the risk of fractures (Theill et al., 2002; 
Boyle et al., 2003). An estrogen deficiency at 
menopause and an androgen deficiency in men 
both  cause  an  unbalanced  increase  in  bone 
turnover,  in  which  bone  resorption  exceeds 
bone formation. Relatively rapid bone loss   
occurs and is accompanied by the destruction of 
bone micro-architecture (Simonet et al., 1997; 
McClung, 2007). In most instances, low bone 
mass is caused by an increase in the number of 
osteoclasts  or  by  excessive  osteoclast  activity 
(Walsh et al., 2005). Osteoclasts are multinucle-
ated giant cells that express tartrate-resistant acid 
phosphatase (TRAP) and calcitonin receptors. 
Osteoclast formation requires macrophage (M) 
CSF and receptor activator of NF-B (RANK) 
ligand  (RANKL;  Ross  and Teitelbaum,  2005; 
Takayanagi et al., 2005). M-CSF, which medi-
ates the survival and proliferation of monocyte/
macrophage precursors, is produced primarily 
by stromal fibroblasts, osteoblasts, and activated 
T cells. RANK is the sole signaling receptor for 
RANKL, which induces the development and 
activation of osteoclasts (Suda et al., 1999). The   
in  vivo  significance  of  the  RANKL–RANK 
signaling pathway has been verified by observa-
tions that the deficiency of either gene in mice 
causes severe osteopetrosis (increased bone mass) 
and  the  disappearance  of  osteoclasts  (Kong   
et al., 1999; Li et al., 2000). Several proinflam-
matory cytokines, such as TNF, IL-1, IL-15, 
IL-17, and IL-23, induce the multinucleation   
of osteoclast precursors, or their commitment 
to the osteoclast phenotype, and may act syner-
gistically with RANKL (Feldmann et al., 2001; 
O’Gradaigh et al., 2004; Sato et al., 2006; Ju   
et al., 2008; O’Brien, 2010).
The pleiotropic inflammatory cytokine IL-20,   
a  member  of  the  IL-10  family  (Blumberg   
et al., 2001; Pestka et al., 2004), is expressed in 
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IL-20 is a proinflammatory cytokine of the IL-10 family that is involved in psoriasis, rheuma-
toid arthritis, atherosclerosis, and stroke. However, little is known about the role of IL-20 in 
bone destruction. We explored the function of IL-20 in osteoclastogenesis and the therapeu-
tic potential of anti–IL-20 monoclonal antibody 7E for treating osteoporosis. Higher serum 
IL-20 levels were detected in patients with osteopenia and osteoporosis and in ovariecto-
mized (OVX) mice. IL-20 mediates osteoclastogenesis by up-regulating the receptor activator 
of NF-B (RANK) expression in osteoclast precursor cells and RANK ligand (RANKL) in 
osteoblasts. 7E treatment completely inhibited osteoclast differentiation induced by macro-
phage colony-stimulating factor (M-CSF) and RANKL in vitro and protected mice from OVX-
induced bone loss in vivo. Furthermore, IL-20R1–deficient mice had significantly higher bone 
mineral density (BMD) than did wild-type controls. IL-20R1 deficiency also abolished IL-20–
induced osteoclastogenesis and increased BMD in OVX mice. We have identified a pivotal 
role of IL-20 in osteoclast differentiation, and we conclude that anti–IL-20 monoclonal 
antibody is a potential therapeutic for protecting against osteoporotic bone loss.
© 2011 Hsu et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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inhibit IL-20 in vitro and in vivo (Hsu et al., 2006; Chen and 
Chang, 2009). We also analyzed all members of the IL-10 
family (IL-10, -19, -20, -22, -24, and -26) to confirm the 
specificity of 7E using ELISA. Only IL-20 was recognized by 
7E (Fig. S1, A and B). Thus, we generated an ovariectomy-
induced osteoporosis mouse model to investigate how IL-20 
was involved in osteoclastogenesis and to examine the thera-
peutic effect of 7E on osteoporotic bone loss.
The serum level of IL-20 was up-regulated in the OVX 
mice but reduced in OVX mice treated with 7E (Fig. 1 B). 
Micro-computed tomography (micro-CT) scans of the mice 
tibia showed less bone loss in OVX mice treated with 7E 
(Fig. 1 C). It also showed a significant dose–response increase 
in the BMD of tibia in those mice (Fig. 1 D). Lower osteoclast 
numbers (N.Oc/BS) and smaller osteoclast areas of bone sur-
face (Oc.S/BS) were observed in 7E-treated OVX mice 
(Fig. 1, E and F). Measurements of serum levels of C-terminal 
telopeptide of collagen (CTX), a marker of bone resorption, 
confirmed that OVX mice had higher bone resorption than 
did sham control mice. 7E-treated OVX mice had lower 
serum CTX than did mIgG-treated OVX control mice 
(Fig. S1 C). Bone histomorphometric analysis showed that 
the OVX procedure caused a significantly lower bone volume 
(Fig. S1 E, BV/TV), trabecular bone thickness (Fig. S1 G, 
Tb.Th), and trabecular number (Fig. S1 F, Tb.N.) in mIgG-
treated OVX mice than in 7E-treated OVX mice. 7E-treated 
OVX mice also showed lower trabecular separation (Fig. S1 
H, Tb.Sp) than mIgG-treated OVX control mice.
7E inhibited osteoclast differentiation
Bone formation is tightly regulated by cross talk between 
osteoblasts and osteoclasts. Unbalanced osteoclastogenesis 
causes bone loss in osteoporosis (Ross and Teitelbaum, 2005; 
Takayanagi  et  al.,  2005). Thus,  we  wanted  to  determine 
whether 7E inhibits the differentiation of osteoclasts, thereby 
protecting OVX mice against bone loss. Osteoclast precursor 
cells were prepared from bone marrow–derived hematopoietic 
stem cells (HSCs), and both M-CSF and soluble (s) RANKL 
were added to the culture to drive osteoclast differentiation. 
We used two culture protocols to analyze the effect of 7E on 
osteoclast differentiation in the early and later stages of osteo-
clastogenesis. M-CSF–derived osteoclast precursor cells were 
cultured  with  40  ng/ml  of  mouse  M-CSF,  100  ng/ml 
sRANKL, and 2 µg/ml 7E for 6 d. TRAP staining was used 
to quantify the number of differentiated osteoclasts. 25 ng/ml 
TNF  was  a  positive  control  for  osteoclast  differentiation. 
There were significantly fewer TRAP+ osteoclasts in the 
7E-treated group than in the mIgG-treated group (Fig. 2, A 
and B). We found almost no TRAP+ osteoclasts in the 7E-
treated group. To clarify whether 7E affected osteoclast differ-
entiation in early or later stages, or both, we first incubated 
the HSCs with 7E or mIgG for 1 h and then added M-CSF 
for another 40 h. The cells were washed and then cultured in 
medium containing M-CSF and sRANKL without 7E for 8 d.   
Early  incubation  with  7E  efficiently  inhibited  osteoclast   
differentiation (Fig. 2, C and D). Thus, 7E blocked both the 
monocytes, epithelial cells, and endothelial cells. IL-20 acts 
on multiple cell types by activating a heterodimer receptor 
complex of either IL-20R1–IL-20R2 or IL-22R1–IL-20R2 
(Dumoutier et al., 2001). It is involved in various inflamma-
tory diseases (Wei et al., 2006), such as psoriasis (Blumberg 
et al., 2001; Wei et al., 2005; Sa et al., 2007), RA (Hsu et al., 
2006), atherosclerosis (Caligiuri et al., 2006; Chen et al., 2006), 
ischemic stroke (Chen and Chang, 2009), and renal failure 
(Li et al., 2008). IL-20 is regulated by hypoxia and inflamma-
tory stimuli such as IL-1 and LPS (Otkjaer et al., 2007; Chen 
and Chang, 2009). IL-20 has recently been reported to regu-
late angiogenesis (Heuzé-Vourc’h et al., 2005; Hsieh et al., 
2006; Tritsaris et al., 2007). IL-20 induces synovial fibroblasts 
to secrete MCP-1, IL-6, and IL-8, and it acts as a proinflam-
matory cytokine (Hsu et al., 2006).
We previously (Hsu et al., 2006) showed that IL-20 is in-
volved in RA and its soluble receptor of IL-20R1 blocked 
IL-20, which reduced the severity of collagen-induced arthritis 
(CIA). Therefore, IL-20 is a promoting factor during the pro-
gression of RA. However, little is known about the function 
of IL-20 in bone resorption or about the function of IL-20   
in  RANKL-RANK  signaling-mediated  osteoclastogenesis. 
Therefore, we explored the effect of anti–IL-20 monoclonal 
antibody 7E on osteoclast differentiation and its therapeutic 
potential to protect against osteoporotic bone loss.
RESULTS
Higher serum IL-20 in patients with osteopenia  
and osteoporosis
IL-20 is involved in the progression of RA, and IL-20R1 
soluble receptor blocked IL-20 and protected against bone 
destruction in a CIA animal model (Hsu et al., 2006). Little   
is known, however, about the pathophysiology of IL-20 in 
osteoporotic bone destruction.  Therefore, we examined whether 
IL-20 was involved in the pathogenesis of osteoporosis. We 
analyzed the IL-20 serum levels in the patients with osteope-
nia and osteoporosis and compared them with those of healthy 
controls. 33 healthy women (age range: 41–60 yr old), 62 
women with osteopenia (age range: 41–67 yr old), and 37 
women with osteoporosis (age range: 40–81 yr old) were in-
cluded in the analysis (Table S1). The serum IL-20 concentra-
tion in osteopenia and osteoporosis patients was significantly 
higher than in healthy controls (Fig. 1 A). The median levels 
of serum IL-20 in the healthy controls, osteopenia, and   
osteoporosis patients were 15.38 pg/ml (25–75th percen-
tiles,  0–109.3  pg/ml),  209.5  pg/ml  (25–75th  percentiles,   
0–453.5  pg/ml),  and  181.3  pg/ml  (25–75th  percentiles, 
20.41–593.3 pg/ml), respectively.
7E protected ovariectomized (OVX) mice against bone 
destruction and increased bone mineral density (BMD)
Osteopenia and osteoporosis patients had more IL-20 in their 
serum than did healthy controls, which suggested that the 
IL-20 might be involved in the pathogenesis of bone loss. We 
generated a mouse anti–human IL-20 monoclonal antibody 
7E and demonstrated its therapeutic potential because it could JEM Vol. 208, No. 9 
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then treated with M-CSF for 6 h. RT quantitative (Q) PCR 
showed that IL-20 mRNA was higher in M-CSF–treated HSCs 
than in controls (Fig. 3 A), which was evidence that M-CSF 
caused endogenous IL-20 expression. In addition, three sub-
units of IL-20 receptor were expressed in the M-CSF–treated 
osteoclast precursor cells (Fig. 3 A) and mature osteoclasts 
(Fig. 3 B). These results suggested that IL-20 acted in an auto-
crine manner on the HSC-derived osteoclast precursor cells.
IL-20 induced RANK expression in M-CSF–derived 
osteoclast precursor cells
The RANKL-RANK signal is critical for osteoclast differen-
tiation (Wada et al., 2006). RANK is expressed on the surface 
of osteoclast precursor cells. To investigate whether IL-20 in-
creases osteoclast differentiation by increasing RANKL-RANK 
signaling, we analyzed RANK expression in M-CSF–derived 
osteoclast precursor cells from bone marrow cells. The cytoplas-
mic RANK mRNA (Fig. 3 C) and surface expression of RANK 
protein (Fig. 3 D) were up-regulated in IL-20–treated osteo-
clast precursor cells. Consistent with its inhibition of osteoclast 
early and later stages of osteoclast differentiation. Furthermore, 
7E markedly down-regulated the transcripts of RANK and 
osteoclast differentiation markers such as c-Fos, cathepsin K, 
NFATc1, and TRAP in the in vitro osteoclast differentiation 
system (Fig. 2, E–I). TNF also increased osteoclast formation. 
We therefore analyzed whether IL-20 directly induced osteo-
clast differentiation or indirectly promoted osteoclast differ-
entiation by inducing  TNF expression. Although  TNF induced 
more osteoclast formation, 7E potently inhibited osteoclast   
formation in the presence of TNF, which suggested that the 
endogenous secretion of IL-20 by osteoclast precursor cells 
independently promotes osteoclast formation (Fig. 2 J).
M-CSF up-regulated IL-20 in HSCs
7E blocked the differentiation of osteoclasts from M-CSF–
derived osteoclast precursor cells (Fig. 2). We hypothesized 
that HSCs or osteoclast precursor cells expressed IL-20, which 
then acted as an autocrine mediator of osteoclastogenesis. To 
test this possibility, we examined IL-20 expression in the bone 
marrow–derived HSCs that had been cultured overnight and 
Figure 1.  A higher serum level of IL-20 was detected in osteopenia and osteoporosis patients. (A) Level of IL-20 in serum from 33 healthy 
women, 62 women with osteopenia, and 37 women with osteoporosis was analyzed. Median levels of IL-20 were 15.38 pg/ml in healthy controls, 209.5 
pg/ml in osteopenia patients, and 181.3 pg/ml in osteoporosis patients. Each box represents the 25–75th percentiles. Lines outside the boxes represent the 
10th and 90th percentiles, and lines inside the boxes represent the median. Data are representative of three independent experiments. **, P < 0.01.  
(B) Serum levels of IL-20 in Sham or OVX mice treated with 3 or 6 mg/kg 7E, control Ab (mIgG), or 10 µg/kg 17-estradiol. The treatment began 1 wk 
after surgery and the treatment was given every 3 d for 2 mo. Values are means ± SD. Data are representative of three independent experiments. **,  
P < 0.01. (C) Representative figures of micro-CT analysis of the right tibia of mice 2 mo after OVX (n = 5 or 6) or sham surgery (n = 5), followed by no 
treatment (OVX, n = 5), 10 µg 17-estradiol/kg/d (n = 6), 6 mg mIgG/kg/3 d (n = 6), 3 mg 7E/kg/3 d (n = 5), or 6 mg 7E/kg/3 d (n = 5). Data are represen-
tative of three independent experiments. (D) BMD in the tibias of each experimental group. Values are means ± SD. Data are representative of three inde-
pendent experiments. *, P < 0.05; **, P < 0.01. (E and F) Osteoclast numbers (E) and osteoclast areas (F) per bone surface in TRAP-stained sections. N.Oc/BS, 
number of osteoclasts per bone surface; Oc.S/BS, osteoclast surface per bone surface. Values are means ± SD. Data are representative of three indepen-
dent experiments. *, P < 0.05; **, P < 0.01.1852 IL-20 mAb inhibits osteoclast differentiation | Hsu et al.
Figure 2.  Anti–IL-20 monoclonal antibody 7E inhibited osteoclast differentiation. Bone marrow cells from the tibias of mice were incubated for 
12 h. Later, nonadherent cells were collected and cultured with 30 ng/ml M-CSF. After 48 h, M-CSF–derived osteoclast precursor cells were treated with  
2 µg/ml 7E, 2 µg/ml mIgG or 25 ng/ml TNF in -MEM with 40 ng/ml M-CSF and 100 ng/ml sRANKL until the end of the experiment. (A) Representative TRAP 
staining of osteoclasts. Data are representative of three independent experiments. (B) Quantitation of TRAP+ osteoclasts per well. Values are means ± SD of 
12 wells. Data are representative of three independent experiments. **, P < 0.01. (C) Representative TRAP staining of osteoclasts. Osteoclasts were cultured 
as described, but 7E was included during the first 2 d of culture in M-CSF. (D) Quantitation of TRAP+ osteoclasts per well. Values are means ± SD of 12 wells. 
Data are representative of three independent experiments. **, P < 0.01. (E–I) Osteoclast precursor cells were treated with M-CSF and sRANKL combined with 
2 µg/ml 7E or 2 µg/ml of control IgG, mRNA was isolated, and the transcripts of RANK, c-Fos, cathepsin K, NFATc1, and TRAP were measured by RTQ-PCR at 
day 6 after culture. Data are the means ± SD of three independent experiments each performed in triplicates. *, P < 0.05. (J) Osteoclast precursor cells were 
treated with M-CSF and sRANKL combined with 25–50 ng/ml TNF and 2 µg/ml 7E or 2 µg/ml of control IgG. The number of TRAP+ osteoclasts per well is 
shown. Values are means ± SD of 12 wells. Data are representative of three independent experiments. *, P < 0.05; **, P < 0.01.JEM Vol. 208, No. 9 
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Figure 3.  Functions of IL-20 in  
osteoclasts. (A) Bone marrow–derived HSCs 
were incubated with 50 ng/ml M-CSF for 6 h. 
mRNA was isolated and IL-20, IL-20R1, IL-20R2, 
and IL-22R1 mRNA expression was measured 
by RTQ-PCR. Values are means ± SD of 5 wells. 
Data are representative of three independent 
experiments. **, P < 0.01. (B) Mature osteo-
clasts were stained for expression of IL-20,  
IL-20R1, IL-20R2, and IL-22R1 protein or with a  
mouse IgG1 (mIgG1) isotype control. (C and  
E) M-CSF–derived osteoclast precursor cells 
were stimulated with 200 ng/ml IL-20 alone 
(C) or in combination with 2 µg/ml 7E (E) for 
the indicated times and RANK mRNA was 
measured by RTQ-PCR. Values are means ± SD 
of 5 wells. Data are representative of three 
independent experiments. *, P < 0.05; **, P < 
0.01. (D and F) M-CSF–derived osteoclast pre-
cursor cells were cultured for 24 h with 200 
ng/ml IL-20 alone (D) or in combination with  
2 µg/ml 7E (F). Cells were scraped and then 
incubated for 30 min with anti–mouse PE-
conjugated RANK antibody or isotype control 
antibody. Surface RANK expression was ana-
lyzed using flow cytometry. Data are represen-
tative of three independent experiments.  
(G) Mature osteoclasts were stimulated with 
200 ng/ml IL-20 for the indicated times and 
cathepsin G mRNA was measured by RTQ-PCR. 
Values are means ± SD of 5 wells. Data are 
representative of three independent experi-
ments. *, P < 0.05 versus untreated controls. 
(H) MC3T3-E1 cells were incubated with IL-20– 
treated OC CM or PBS-treated OC CM for  
20 h, and the production of sRANKL was mea-
sured by ELISA. Data are the means ± SD of 
three independent experiments each per-
formed in triplicates. *, P < 0.05 versus un-
treated controls; #, P < 0.05 versus OC CM.  
(I) Control or IL-20–treated OC CM was incu-
bated with 10 µM of a cathepsin G–specific 
inhibitor (TPCK) for 1 h at 37°C before MC3T3-
E1 culture for 20 h. sRANKL concentration in 
the final culture medium was determined by 
ELISA. Data are the means ± SD of three inde-
pendent experiments each performed in tripli-
cates. *, P < 0.05 versus OC CM; #, P < 0.01 
versus IL-20–treated OC CM.
differentiation, 7E inhibited both the expression of RANK tran-
scripts (Fig. 3 E) and the surface expression of RANK protein 
(Fig. 3 F). These results are evidence that IL-20 acts as an osteo-
clastogenic cytokine on osteoclast precursor cells.
IL-20 induced cathepsin G expression in osteoclasts
Cathepsin G, highly expressed in osteoclasts, is capable of 
shedding the extracellular domain of RANKL from osteoblasts 
to  generate  active  soluble  RANKL 
and inducing the differentiation and 
activation of osteoclast precursors (Wilson et al., 2008). IL-20 
induced the expression of cathepsin G in M-CSF–derived 
mature osteoclasts (Fig. 3 G). Therefore, we hypothesized that 
IL-20–treated osteoclasts produce a high level of cathepsin G 
and subsequently cleave membrane-bound RANKL to gener-
ate a soluble form of RANKL, which further stimulates osteo-
clast differentiation. To confirm this mechanism, we incubated 
osteoblastic MC3T3-E1 cells with IL-20–treated osteoclast   1854 IL-20 mAb inhibits osteoclast differentiation | Hsu et al.
in osteoblasts, we incubated the MC3T3-E1 cells with IL-20 
and analyzed RANKL expression using RTQ-PCR and flow 
cytometry. RANKL expression was time-dependently higher 
in IL-20–treated MC3T3-E1 cells than in untreated controls, 
and it peaked 6 h after treatment (Fig. 4 D). The surface ex-
pression of RANKL protein was also higher in IL-20–treated 
MC3T3-E1 cells (Fig. 4 E).
7E inhibited IL-20–induced RANKL expression in osteoblasts
RANKL  expression  was  up-regulated  in  IL-20–treated 
MC3T3-E1 cells (Fig. 4, D and E). To confirm that 7E inhib-
its IL-20-induced RANKL expression, we co-treated the 
cells  with  IL-20  and  7E.  RTQ-PCR  detected  almost  no 
RANKL transcripts in co-treated cells (Fig. 4 F), and surface 
RANKL protein expression was lower in co-treated cells than 
in cells treated only with IL-20 (Fig. 4 G). These results in-
dicated that IL-20 is an upstream activator of RANKL ex-
pression in osteoblasts and that 7E inhibits IL-20–induced 
RANKL expression. These in vitro results are evidence that 
IL-20 is an upstream mediator of RANKL and is involved   
in osteoclastogenesis.
IL-20R1 deficiency inhibited osteoclast differentiation
IL-20 up-regulated RANK expression in osteoclast precursor 
cells  and  up-regulated  RANKL  expression  in  osteoblasts 
(Figs. 3 and 4). Our previous study (Hsu et al., 2006) showed 
conditioned medium (OC CM) for 20 h. ELISA assay showed 
that  IL-20–treated  OC  CM  cleaved  a  large  amount  of 
sRANKL derived from MC3T3-E1 cells (Fig. 3 H). We also 
directly treated MC3T3-E1 cells with IL-20 alone as a con-
trol. There were no differences in the amount of sRANKL in 
the media between the untreated and IL-20–treated MC3T3-
E1  cells. To  confirm  that  the  cleavage  of  RANKL  was   
cathepsin G dependent, we used a specific cathepsin G in-
hibitor (TPCK, 10 µM) to block the protease activity of 
cathepsin G. The result confirmed our hypothesis (Fig. 3 I). 
Therefore, IL-20 was also involved in osteoclastogenesis by 
inducing cathepsin G and modulating sRANKL production 
by osteoblast.
IL-20 targeted osteoblasts and up-regulated  
RANKL expression
Increased RANKL expression in osteoblasts is also a key 
factor  for  osteoclastogenesis  (Wada  et  al.,  2006). We  used 
RTQ-PCR (Fig. 4 A) and cytochemical staining (Fig. 4 B) to 
show that IL-20 and its receptor subunit were expressed in 
osteoblastic MC3T3-E1 cells. Phosphorylation of JNK, ERK, 
AKT, and p38 were detected in IL-20–treated MC3T3-E1 
cells (Fig. 4 C), more evidence that IL-20 was endogenously 
expressed in osteoblasts and triggered signal transduction in them 
in an autocrine manner. To determine whether IL-20 con-
tributes to osteoclastogenesis by inducing RANKL expression 
Figure 4.  Functions of IL-20 in osteoblastic MC3T3-E1 cells. (A) The expression of IL-20 and its receptors in MC3T3-E1 cells was analyzed using 
RTQ-PCR. (B) MC3T3-E1 cells were stained for expression of IL-20, IL-20R1, IL-20R2, IL-22R1, or isotype control (mIgG1). (C) MC3T3-E1 cells were incu-
bated with IL-20 for the indicated time periods, and cell lysates were analyzed by immunoblotting for the indicated protein. Data are representative of 
three independent experiments. (D and F) MC3T3-E1 cells were treated with 200 ng/ml IL-20 alone (D) or in combination with 2 µg/ml 7E (F) for the indi-
cated times and RANKL mRNA was analyzed by RTQ-PCR. Values are means ± SD of 5 wells. Data are representative of three independent experiments.  
*, P < 0.05; **, P < 0.01. (E and G) MC3T3-E1 cells were cultured for 16 h with 200 ng/ml IL-20 alone (E) or in combination with 2 µg/ml 7E (G). Surface 
RANKL expression was analyzed using flow cytometry. Data are representative of three independent experiments.JEM Vol. 208, No. 9 
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from IL-20R1/ mice did not have functional IL-20R1 
protein, we used IL-19 to target the cells because IL-19 binds 
only to IL-20R1/IL-20R2. IL-19 induced IL-10 expression 
in PBMCs through the IL-20R1–IL-20R2 receptor complex 
(Jordan et al., 2005).  We isolated the PBMCs from IL-20R1+/+, 
IL-20R1+/, and IL-20R1/ mice and then treated them 
with IL-19. IL-19–induced IL-10 expression was abolished in 
IL-20R1/ PBMCs (Fig. S2 E), which confirmed that the 
IL-20R1 gene had been successfully deleted in IL-20R1/ 
mice. The  BMD  in  the  tibias  was  significantly  higher  in   
IL-20R1/ mice than in IL-20R1+/+ mice when they reached 
the age of 28 wk (Fig. 5 A). Bone histomorphometric analysis 
showed that bone volume and trabecular bone thickness were 
also higher in IL-20R1/ mice than in IL-20R1+/+ mice 
(Fig. S3, A–D). We also analyzed the RANK and RANKL 
level in the proximal tibia of WT and IL-20R1/ mice. 
RTQ-PCR revealed that both RANKL and RANK were 
down-regulated  in  IL-20R1/  mice  compared  with WT 
mice (Fig. S3, E and F), demonstrating that IL-20 is involved 
in the regulation of the RANK-RANKL in vivo. Further-
more, the transcripts of RANK and osteoclast differentiation 
markers were analyzed in the in vitro osteoclast differentia-
tion system. RANK  and osteoclast differentiation markers 
such as c-Fos, cathepsin K, NFATc1, and TRAP were mark-
edly down-regulated in IL20R1-deficient cells (Fig. S4, A–E). 
that IL-20R1 was significantly up-regulated in CIA animal 
model and that treatment with the soluble receptor of IL-20R1 
ameliorated the severity of CIA, which suggested that IL-20R1 
is critical for IL-20 signaling. To confirm the critical involve-
ment of IL-20 in osteoclastogenesis, we generated IL-20R1 
knockout mice and analyzed the effect of IL-20R1 deficiency 
on IL-20–induced osteoclastogenesis. To generate IL-20R1 
knockout mice, we first examined whether the deletion of 
exon 2 completely blocked the expression of IL-20R1. The 
deletion of exon 2 of IL-20R1 abolished the translation of 
IL-20R1-EGFP fusion protein, which showed that exon 2 is 
a target for IL-20R1 gene disruption (Fig. S2 A). To block 
IL-20R1 gene expression, we used homologous recombina-
tion to delete exon 2 (Fig. S2 B) and Southern blotting with 
the probe annealed to 3 of the target sequence to verify the 
deletion of the IL-20R1 allele (Fig. S2 C). IL-20 binds to 
one of its two receptor complexes: IL-20R1–IL-20R2 and 
IL-20R2–IL-22R1. In the coimmunoprecipitation assay, the 
lysates of lung tissue from WT (+/+), heterozygote (+/), 
and knockout (/) mice were incubated with His-tagged 
IL-20 and pulled down by anti-His antibody. The pulled-
down pellet was analyzed using immunoblotting with anti-
bodies against IL-20, IL-20R1, IL-20R2, and IL-22R1. No 
IL-20R1  protein  was  detected  in  the  lung  lysates  from   
IL-20R1/ mice (Fig. S2 D). To confirm that cells isolated 
Figure 5.  IL-20R1 deficiency increased BMD in vivo and inhibited IL-20–induced osteoclast differentiation and signal transduction in vitro. 
(A) BMD in the tibias of 28-wk-old IL-20R1 WT (+/+), heterozygote (+/), and knockout (/) mice (n = 5/group). Values are means ± SD of five mice. 
Data are representative of three independent experiments. *, P < 0.05. (B) M-CSF–derived osteoclast precursor cells from the indicated mice were treated 
with M-CSF and sRANKL combined with 200 ng/ml IL-20. Values are means ± SD of five mice. Data are representative of three independent experiments. 
*, P < 0.05. (C) M-CSF–derived osteoclast precursor cells from the indicated mice were treated with M-CSF and sRANKL combined with 2 µg/ml 7E or  
2 µg/ml mIgG. Values are means ± SD of five mice. Data are representative of three independent experiments. **, P < 0.01. (D) M-CSF–derived osteoclast 
precursor cells from IL-20R1+/+ and IL-20R1/ mice were cultured with IL-20 for the indicated time periods, and the cell lysates were immunoblotted for 
the indicated protein. Data are representative of three independent experiments. (E) Bone marrow–derived HSCs from WT mice were incubated with  
40 ng/ml M-CSF with 2 µg/ml 7E or 2 µg/ml of control mIgG for 48 h followed by 50 ng/ml sRANKL for 48 h. Cell lysates were immunoblotted for the 
indicated protein. Data are representative of three independent experiments.1856 IL-20 mAb inhibits osteoclast differentiation | Hsu et al.
Because IL-20 was endogenously expressed in mature osteo-
blast,  we  hypothesized  that WT  osteoblast,  in  response  to 
IL-20, may secrete TNF which enhanced osteoclast differ-
entiation  independent  of  IL-20R1  signaling. To  test  this 
possibility, we compared the induction of TNF transcript 
in response to IL-20 in mature osteoblast from WT and   
IL-20R1/ mice. IL-20 up-regulated TNF expression in WT 
osteoblasts but not in IL-20R1-deficient osteoblasts (Fig. S5 B). 
The observation indicated that IL-20R1 deficiency affected 
the function of osteoblasts. In addition, the WT osteoblasts 
produced more RANKL in response to IL-20 than IL-20R1–
deficient osteoblasts did (Fig. S5 C), which may result in more   
osteoclast differentiation from  WT osteoblast/IL-20R1/ osteo-
clast precursor co-culture than from IL-20R1/ osteoblast/WT 
osteoclast precursor co-culture.
IL-20 promoted osteoclastogenic signal transduction  
in M-CSF–derived osteoclast precursor cells
RANKL–RANK signaling-mediated NFATc1 activation is 
pivotal for osteoclast differentiation. To determine whether 
IL-20 signaling contributes to the alteration of osteoclasto-
genic signaling, we treated M-CSF–derived osteoclast pre-
cursor cells with IL-20 and found that IL-20 promoted the 
activation of NF-B, TRAF6, STAT3, NFATc1, and c-Fos 
(Fig. 5 D). The activation of IL-20–induced osteoclastogenic 
signals was lower in IL-20R1/ than in IL-20R1+/+ mouse-
derived osteoclast precursor cells. In addition, 7E almost totally 
In  IL-20R1+/+  mice, TRAP+  osteoclasts  were  higher  in   
M-CSF–derived osteoclast precursor cells treated with IL-20. 
In  both  IL-20R1+/  and  IL-20R1/  mice,  however,  the 
basal level of TRAP+ osteoclasts was lower (Fig. 5 B). In addi-
tion, osteoclast differentiation was significantly inhibited in 
the IL-20R1/ group treated with IL-20 (Fig. S4 F), which 
indicated that IL-20R1 signaling is critical for IL-20-mediated 
osteoclastogenesis. To examine the inhibitory effect of 7E on 
osteoclast differentiation, we compared the TRAP+ osteoclasts 
derived from the IL-20R1+/+, IL-20R1+/, and IL-20R1/ 
osteoclast precursor cells. 7E completely blocked in vitro osteo-
clast differentiation in all three types of mice (Fig. 5 C), which 
confirmed the pivotal role of IL-20 in osteoclast differentia-
tion and that 7E blocks osteoclastogenesis.
Furthermore, we performed the mixed co-cultures of   
osteoclasts and osteoblasts by reciprocal combinations of these 
two cell populations from WT and IL-20R1/ mice to de-
termine the relative contribution of each to osteoclastogen-
esis. IL-20 is critical to both osteoclast and osteoblast because 
IL-20R1 deficiency impaired osteoclast differentiation in the 
mixed co-cultures of both WT osteoblast/IL-20R1/ osteo-
clast precursors and IL-20R1/ osteoblast/WT osteoclast 
precursors (Fig. S5 A). The co-cultures of IL-20R1/ osteo-
clast precursors with WT osteoblast did not show as much 
impairment  of  osteoclast  differentiation  as  the  osteoblast- 
free system (Fig. 5 B) in which M-CSF and sRANKL were 
added to IL-20R1/ osteoclast precursors to replace osteoblast.   
Figure 6.  IL-20R1 deficiency protected mice from OVX-induced bone loss. (A) Micro-CT analysis of the right tibias of IL-20R1+/+, IL-20R1+/, and 
IL-20R1/ mice 2 mo after OVX treatment (n = 5/group). Data are representative of three independent experiments. (B) BMD in the tibias of OVX mice. Values are 
means ± SD of five mice. Data are representative of three independent experiments. (C and D) The number of osteoclasts (C) and osteoclast areas (D) per bone sur-
face in TRAP-stained sections. N.Oc/BS, number of osteoclasts per bone surface; Oc.S/BS, osteoclast surface per bone surface (n = 5). Values are means ± SD of five 
mice. Data are representative of three independent experiments. *, P < 0.05 versus corresponding sham-operated mice; #, P < 0.05 versus OVX-IL-20R1+/+ mice.JEM Vol. 208, No. 9 
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progenitor cells, CFU-GEMMs. One study (Liu et al., 2003) 
showed  that  IL-20  specifically  promoted  the  in  vitro  and   
in vivo proliferation of CFU-GEMMs. We showed that M-CSF 
up-regulated IL-20 in osteoclast precursor cells. IL-20, in an 
autocrine  manner,  targeted  osteoclast  precursor  cells  and  in-
creased the expression of RANK. In addition, IL-20 activated 
osteoclastogenic signaling and 7E inhibited the activation of 
NFATc1, the master regulator for osteoclast differentiation. 
Therefore, we hypothesize that IL-20 contributes to osteoclasto-
genesis by promoting both the survival and the expansion of   
osteoclast precursor cells and increasing RANKL-induced activity. 
In the osteoclast differentiation assay, 7E blocked both early 
and later stage differentiation, which supports our hypothesis.
Cathepsin G is also a chemoattractant for osteoclast pre-
cursors by proteolytically activating PAR-1 (Wilson et al., 2009). 
In the present study, IL-20 up-regulated the expression of   
cathepsin G in osteoclasts, which dose-dependently induced 
the cleavage of RANKL from the surface membrane of   
osteoblasts. Therefore, we speculate that IL-20 acts on osteo-
clasts to produce a large amount of cathepsin G in bone 
microenvironment. The IL-20–induced cathepsin G, in turn, 
recruits more osteoclast precursors that differentiate into 
mature osteoclasts and produce more cathepsin G, which 
leads to the generation of sRANKL.
The RANKL–RANK signaling mechanism is one path-
way of osteoclast formation and activity (Kong et al., 1999;   
Li  et  al.,  2000). We  found  that  IL-20  increased  RANKL 
mRNA and RANKL protein expression in osteoblasts, which 
suggested that IL-20 is an upstream regulator for RANKL 
expression. RANKL expression is also up-regulated in many 
malignant tumor cells, and is involved in cancer-associated 
bone destruction, tumor metastasis, and tumor-induced oste-
olysis (Park et al., 2007; Wilson et al., 2008). We previously 
(Hsing et al., 2006) showed that IL-20 is expressed in squa-
mous cell carcinoma of the skin, tongue, esophagus, and lung. 
However, the association of IL-20 with tumor progression 
and metastasis has not been clarified. It is therefore necessary to 
explore the effects of 7E on cancer-associated bone metastasis 
and bone erosion.
Soluble RANK antagonists and RANKL inhibitors such 
as osteoprotegerin and anti-RANKL antibody are inhibitors 
of bone resorption in clinical studies, presumably because of 
their effects on osteoclasts. One therapeutic drug to treat osteo-
porosis is denosumab, an anti-RANKL antibody (Kostenuik, 
2005; McClung, 2006). Our results also showed that 7E pro-
tected OVX mice against osteoporotic bone loss and increased 
their BMD. In the in vitro assay, we showed that 7E reduced 
not only the number of TRAP+ osteoclasts, but also the ex-
pression of RANK in M-CSF–derived osteoclast precursor 
cells and of RANKL in osteoblasts. In addition, 7E almost   
totally prevented the RANKL-induced activation of TRAF6, 
c-Fos, NFATc1, and STAT3 because it down-regulated RANK 
expression in osteoclast precursors. Thus, 7E shows promise as 
a therapeutic drug for protection against bone destruction.
BMD is regulated by osteoclastogenic and osteoblasto-
genic activity (Walsh et al., 2005). IL-20R1 deficiency protected 
prevented the RANKL-induced activation of TRAF6, c-Fos, 
NFATc1, and STAT3, which suggested that IL-20 had trig-
gered the osteoclastogenic signals and was a costimulatory 
factor for osteoclastogenesis (Fig. 5 E).
IL-20R1 deficiency protected OVX mice against bone loss
To confirm the in vivo role of IL-20 in osteoclast differentia-
tion, we used micro-CT analysis, in a model of OVX-induced 
osteoporosis, to investigate whether IL-20R1 receptor signal-
ing was crucial for controlling BMD (Fig. 6 A). OVX induced 
a  significant  loss  of  BMD  and  increased  N.Oc/BS  and   
Oc.S/BS in IL-20R1+/+ mice but not in IL-20R1/ mice 
(Fig. 6, B–D). Measurements of serum CTX confirmed that 
OVX increased bone resorption in IL-20R1+/+ mice but not 
in IL-20R1/ mice (Fig. S6 A). OVX induced bone loss in 
IL-20R1+/+ mice. However, no significant bone loss occurred   
in OVX-IL-20R1/ mice. Parameters of trabecular struc-
ture were also differentially affected by OVX in IL-20R1+/+ 
and IL-20R1/ mice because bone volume, trabecular bone 
thickness, trabecular number, and trabecular separation were 
more substantially deteriorated by OVX in IL-20R1+/+ than 
in IL-20R1/ mice (Fig. S6, C–F). Collectively, these results 
showed that IL-20 was important for osteoclast differentia-
tion and that IL-20/IL-20R1 signaling was critical for regu-
lating BMD during metabolic bone disease.
DISCUSSION
We showed that IL-20 was higher both in patients with 
osteoporotic bone loss and in OVX mice. IL-20 stimulates 
osteoclast differentiation and blocking IL-20 activity with the 
specific anti–IL-20 monoclonal antibody 7E has therapeutic 
potential for osteoporotic bone loss. The conventional wis-
dom is that M-CSF and RANKL are both necessary and suf-
ficient for osteoclast differentiation. However, we showed that 
IL-20 endogenously secreted from HSCs is also essential for 
osteoclast differentiation; our evidence is that 7E completely 
blocked osteoclast differentiation in the presence of M-CSF 
and  RANKL.  In  the  correlation  between  IL-20  and  the 
RANKL–RANK  axis,  we  found  that  IL-20  up-regulated 
RANK  expression  on  osteoclast  precursors  derived  from 
bone marrow cells. In addition, IL-20 caused RANKL ex-
pression on osteoblasts. Even though TNF also promoted 
osteoclast formation, 7E potently inhibited osteoclast differ-
entiation in the presence of TNF, which suggested that IL-20 
may act independently on osteoclast differentiation. Treat-
ment with 7E prevented IL-20 from inducing RANK and 
RANKL expression. IL-20–induced osteoclast differentiation 
was inhibited in IL-20R1/ mouse-derived osteoclast pre-
cursor cells. We therefore conclude that IL-20R1 is important 
in IL-20–mediated osteoclastogenesis, and that IL-20 is an 
upstream  activator  of  RANKL-RANK  signaling.  IL-20  is 
pivotal in osteoclast differentiation because it targeted not 
only osteoclast precursor cells but also osteoblasts.
Osteoclasts originate from hematopoietic progenitor cells, 
probably from CFU granulocyte-macrophages (GMs; Menaa 
et al., 2000). CFU-GMs are different from multipotential 1858 IL-20 mAb inhibits osteoclast differentiation | Hsu et al.
of IL-20 in osteoclast differentiation, and we conclude that 
using 7E to inhibit IL-20 is a potential therapeutic strategy 
for protecting against osteoporotic bone loss.
MATERIALS AND METHODS
Patients. 243 women (age range: 40–84 yr old) participating in a community-
based chronic disease prevention study conducted from 2008 to 2009 by the 
Department of Family Medicine, National Cheng Kung University Hospital, 
were recruited for this study. Individuals with known metabolic bone dis-
eases, taking any medications likely to influence BMD, who were bedridden, 
using steroids, alcohol dependent, or with a history of hypertension, diabetes 
mellitus,  arthrosclerosis,  renal  disease,  or  cancer  were  excluded  from  this 
study. BMD for all study participants was determined using dual energy 
x-ray absorptiometry (DXA) of the lumbar spine, hip, and femoral neck. 
According to World Health Organization criteria, the participants were cate-
gorized into three groups based on the DXA results: (1) normal BMD (T ≤ 1); 
(2) osteopenia (2.5 ≤ T ≤ 1); and (3) osteoporosis (T ≤ 2.5). Written 
informed consent was obtained and the study was approved by the Ethics 
Committee of National Cheng Kung University Hospital. Blood samples 
were collected and serum was prepared by nurses according to standard pro-
cedures. Blood was centrifuged (2,000 rpm for 10 min at 4°C), and serum 
was collected. All samples were stored at 80°C until used. Levels of IL-20 
in the serum of the participants were determined using a human IL-20 
ELISA kit (PeproTech) according to the manufacturer’s instructions.
Ovariectomy-induced bone loss model and treatments. All animal 
experiments were conducted according to the protocols based on the National 
Institutes of Health standards and guidelines for the care and use of experi-
mental animals. The research procedures were approved by the Animal Ethics 
Committee of National Cheng Kung University in Taiwan. 14-wk-old   
female  BALB/c  mice  under  general  anesthesia  (50  mg  pentobarbital/kg 
body weight; Sigma-Aldrich) were OVX or sham operated (Sham Controls). 
The experiments began 1 wk after surgery and the mice were divided into 
six groups: sham controls (n = 5), OVX mice without treatment (n = 5), and 
OVX mice treated with 10 µg 17-estradiol/kg/d (n = 6; Sigma-Aldrich), 
6 mg mIgG/kg/3 d (n = 6; Millipore), 3 mg 7E/kg/3 d (n = 5), or 6 mg 7E/
kg/3 d (n = 5). All the mice were given an overdose of pentobarbital 2 mo 
after the treatments had begun, and their tibias were aseptically collected, 
cleaned of adherent soft tissue, and analyzed with micro-CT scanning. Blood 
was centrifuged at 2,000 rpm for 10 min at 4°C, and serum was collected. Levels 
of IL-20 in the serum were determined using an IL-20 ELISA kit according 
to the manufacturer’s instructions. To calculate the number of osteoclasts on 
the bone surface, the tibias were collected and frozen sectioned for TRAP 
staining 3 wk after the first treatment.
Micro-CT. The  tibia  metaphyses  were  analyzed  in  vivo  on  a  micro-CT   
(1076; SkyScan) with a high resolution low-dose x-ray scanner. BMD, a three- 
dimensional bone characteristic parameter, was analyzed in 50 consecutive slices. 
Trabecular bone volume (BV/TV), trabecular bone thickness (Tb.Th), trabecular 
number (Tb.N.), and trabecular separation (Tb.Sp) were measured using the   
software developed for bone histomorphometry (CT-analyzer software; SkyScan).
RTQ-PCR. Total mRNA was isolated. Reverse transcription was done 
with reverse transcriptase according to the manufacturer’s protocol (Takara 
Bio Inc). IL-20, IL-20R1, IL-20R2, IL-22R1, RANK, RANKL, cathepsin 
G, cathepsin K, c-Fos, TRAP, NFATc1, and TNF expression was then ampli-
fied on a thermo cycler (LC 480; Roche), with SYBR green (Roche) as the 
interaction agent. Quantification analysis of mRNA was normalized with 
mGAPDH as the housekeeping gene. Relative multiples of change in mRNA 
expression was determined by calculating 2Ct.
In vitro osteoclastogenesis assay. Bone marrow cells from the tibias of 
WT C57BL/6, IL-20R1+/, or IL-20R1/ mice were incubated for 12 h 
at 37°C in 5% CO2. Later, nonadherent cells were collected and seeded in 
24-well plates (2 × 106 cells per well) and cultured in the same medium 
mice from OVX-induced bone loss. This finding is consistent 
with  our  finding  that  serum  IL-20  levels  were  higher  in   
patients  with  osteopenia  and  osteoporosis  than  in  healthy 
controls. This suggested that the osteoclastogenic activity of 
IL-20 might be activated only during pathological conditions 
such as estrogen deficiency or OVX-induced osteoporosis. To 
prove this, we treated healthy WT mice with 7E and found 
that it had no significant effect on their BMD compared with 
untreated mice. In addition, there was no significant differ-
ence  in  serum  IL-20  levels  between  sham-operated  mice 
treated with PBS and those treated with 7E, which indicated 
that serum IL-20 antibody from 7E treatment did not inter-
fere with the ELISA analysis of IL-20 in 7E-treated OVX 
mice (unpublished data). Moreover, we still observed some in 
vitro osteoclast differentiation from osteoclast precursor cells 
of IL-20R1/ mice. This may be attributable to the alterna-
tive IL-20R2–IL-22R1 receptor complex signaling. Expres-
sion of all the three receptor subunits on osteoclast precursor 
cells suggested this possibility. In vitro osteoclast differentia-
tion was inhibited in osteoclast precursor cells derived from 
IL-20R1/ mice with no effect of addition of IL-20. We hy-
pothesize that the response threshold of IL-20 in IL-20R1/ 
mice is much higher than in WT mice because of different 
receptor complex signaling. No significant difference in BMD 
was observed in the 8-wk-old IL-20R1+/+, IL-20R1+/, and 
IL-20R1/ mice. However, IL-20R1/ mice had signifi-
cantly higher BMD than did IL-20R1+/+ mice when they 
reached the age of 28 wk. This difference raised the possibility 
that an age-related estrogen deficiency might affect IL-20 
levels, the activity of which was inhibited in IL-20R1/ 
mice. Additional studies are needed to explore the detailed 
molecular mechanism of estrogen’s regulation of IL-20. The 
intercross co-cultures of osteoclast precursors with osteoblas-
tic cells from WT and IL-20R1/ mice demonstrated that 
the deficiency of IL-20R1 affected both osteoclast precursors 
and osteoblasts that impaired osteoclast differentiation. The 
co-cultures of IL-20R1/ osteoclast precursors with WT 
osteoblastic cells did not show as much impairment of osteo-
clast differentiation as the osteoblast-free system (Fig. 5 B). 
This may be attributed to IL-20–induced TNF production in 
the WT osteoblasts. Thus, IL-20 and IL-20R1 signaling are 
crucial not only in osteoclast differentiation, but also in the 
function of osteoblast. These findings support the hypothesis 
that IL-20 produced by osteoblasts and osteoclasts stim-
ulate IL-20R1 signaling, which mediates the cross talk be-
tween osteoclasts and osteoblasts and regulates the bone 
remodeling. Furthermore, whether IL-20 is also involved in 
osteoblast differentiation is not well understood. It is neces-
sary to further investigate the mechanism that IL-20 uses to 
maintain the balance between osteoclastogenesis and osteo-
blastogenesis in metabolic bone destruction and inflammatory 
bone diseases.
In summary, our findings provide evidence that IL-20 
is an osteoclastogenic cytokine that up-regulates RANK 
on osteoclast precursor cells and RANKL on osteoblasts and 
affects the functions of both cells. We identified a pivotal role JEM Vol. 208, No. 9 
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collected  and  analyzed  using  immunoblotting  with  specific  antibodies: 
TRAF6 (Epitomics), c-Fos (Santa Cruz Biotechnology, Inc.), NFATc1 (Santa 
Cruz Biotechnology, Inc.), phospho–NF-B (Cell Signaling Technology), 
and phospho-STAT3 (Cell Signaling Technology). To assay the inhibitory effect 
of 7E on osteoclastogenic signals, bone marrow–derived HSCs from WT 
mice were incubated for 48 h with 40 ng/ml M-CSF and either 2 µg/ml 7E or 
2 µg/ml of control mIgG. The cells were then treated with 50 ng/ml sRANKL 
for 48 h. Cell lysates were collected for osteoclastogenic signal analysis.
Generating IL-20R1 knockout mice. A 14-kb IL-20R1 locus subclone 
was sequenced and found to contain exon 2. A targeting vector containing a 
6.3-kb NotI and EcoRI fragment (5 region of homology) and a 4.2-kb 
BamHI and SpeI fragment (3 region of homology) was constructed. Exon 2 
was replaced in the targeted locus with a loxP-flanked Neo cassette driven by 
an HSV-TK promoter in the opposite direction of IL-20R1. The targeting 
vector was electroporated into C57BL/6 embryonic stem cells and, using 
nested-set PCR analysis, G418-resistant colonies were screened for homolo-
gous recombination. Positive colonies were expanded, and that the 5 and 
3 arms were targeting the locus was confirmed using Southern blotting with 
probes flanking the targeting arms. Transient transfection with a plasmid ex-
pressing Cre recombinase deleted the Neo cassette. A PCR genotyping strat-
egy to distinguish IL-20R1+/+ versus IL-20R1+/ versus IL-20R1/ was 
established using specific primers. IL-20R1/, IL-20R1+/, and WT con-
trols were maintained on a B6 background. IL-20R1+/+, IL-20R1+/, and 
IL-20R1/ mice were OVX or sham operated. Their tibias were analyzed 
using micro-CT or else paraffin-sectioned for TRAP staining. The slides 
were counterstained with hematoxylin.
Primary osteoblast culture. Primary osteoblasts were isolated from cal-
varia of 1-d-old mice by serial digestion (Datta et al., 2005). In brief, calvaria 
was dissected and subjected to sequential digestions in 2 mg/ml collagenase A 
and 0.25% trypsin for 20, 40, and 90 min. Cells from the third digestion   
were rinsed, counted, and plated in -MEM at a density of 20,000/cm2. Pri-
mary cultures were used without passage.
Isolation of CD11b+ monocytes. Single-cell suspensions of the spleen 
were obtained by mechanically disrupting the tissue with a syringe plunger 
in serum-free -MEM. Red blood cells were removed using ACK lysing 
buffer. Splenocytes were labeled with IMag (BD) anti–mouse CD11b beads 
according to the manufacturer’s instructions. After labeling, the cells were 
separated using the IMagnet (BD), and the positive (CD11b+) fractions were 
collected and resuspended in -MEM containing 10% FBS. The purity of 
CD11b+ monocyte was verified to be greater than 94% by FACS analysis.
Osteoblast differentiation and co-culture of osteoblasts with osteo-
clast precursors. Osteoblast differentiation from primary calvarial cells was 
induced by culturing in -MEM containing 10% FBS, 200 µM ascorbic acid, 
10 mM -glycerophosphate, and 10 nM dexamethasone (Sigma-Aldrich). 
The culture media was replaced once every 2 d. Osteoblast differentiation 
was evaluated and confirmed by the measurement of alkaline phosphatase 
and alizarin red S staining. Co-culture of osteoblasts with osteoclast precur-
sors was performed by adding CD11b+ monocytes (5 × 104 cells/well) onto 
the layer of mature osteoblasts (20,000/cm2) and incubated for 9 d in -MEM 
supplemented with 10% FBS and 10 nM vitamin D3 (Sigma-Aldrich). To 
calculate the number of osteoclasts, the cells were fixed in acetone and stained 
for TRAP using an acid phosphatase kit (Sigma-Aldrich). TRAP-positive multi-
nucleated cells containing three or more nuclei were considered as osteoclasts.
Statistical analysis. Prism 5.0 (GraphPad Software) was used for the statis-
tical analysis. A one-way ANOVA nonparametric test (Kruskal-Wallis test) 
was used to compare the data between groups. Post hoc comparisons were 
done using Dunn’s multiple comparison test. The results of serum IL-20 level 
in osteoporosis patients are expressed as box plots. Each box represents the 
25–75th percentiles. Lines outside the boxes represent the 10th and the 90th 
percentiles. Lines inside the boxes represent the median. Other results are ex-
pressed means ± SD. P-values <0.05 were considered significant.
supplemented with 30 ng/ml of recombinant mouse M-CSF (PeproTech). 
After 48 h, M-CSF–derived osteoclast precursor cells were cultured with 
40 ng/ml of mouse M-CSF and 100 ng/ml sRANKL (PeproTech) until the 
end of the experiment. To analyze the effect of 7E in the early stage of osteo-
clast differentiation, bone marrow cells were cultured for 12 h. Nonadherent 
cells were seeded in 24-well plates (2 × 106 cells per well) and cultured in 
-MEM containing 2 µg/ml 7E or 2 µg/ml mIgG, after which 40 ng/ml 
M-CSF was added. After 40 h, the treatment ended, and the cells were washed 
with serum-free culture medium and then incubated with 40 ng/ml M-CSF 
and 100 ng/ml sRANKL for 8 d. In another experiment, to analyze the 
effect of 7E in the later stage of osteoclast differentiation, M-CSF–derived 
osteoclast precursor cells were treated with 2 µg/ml 7E or 2 µg/ml mIgG in 
-MEM with M-CSF and sRANKL for 6 d. To assay the effects of TNF and 
IL-20 on osteoclast differentiation, M-CSF–derived osteoclast precursor cells 
were treated with 25–50 ng/ml of mouse TNF (R&D Systems) plus 2 µg/ml 
7E in -MEM with M-CSF and sRANKL for 8 d. The culture medium was 
changed every 2 d for all differentiation experiments. To calculate the num-
ber of osteoclasts, the cells were fixed in acetone and stained for TRAP using 
an acid phosphatase kit (Sigma-Aldrich). TRAP-positive multinucleated cells 
containing three or more nuclei were considered as osteoclasts.
Flow cytometry. M-CSF–derived osteoclast precursor cells were cultured 
for 24 h with the indicated concentrations of mouse IL-20, mIgG, 7E, or 
both mouse IL-20 and 7E. The cells were scraped, incubated for 30 min with 
5 µg/ml PE-conjugated antibody against mouse RANK (eBioscience) or iso-
type control antibody, and then analyzed using a flow cytometer (FACSCali-
bur; BD). To assay RANKL production, MC3T3-E1 cells were stimulated 
with 200 ng/ml mouse IL-20, trypsinized, and then stained with PE-conjugated 
antibody against RANKL (eBioscience) for flow cytometric analysis.
ELISA. To test the specificity of 7E, cytokines of the IL-10 family (IL-10,   
-19, -20, -22, -24, and -26) were coated on the plate with various concentra-
tions and analyzed for their binding with 1 µg/ml anti–IL-20 monoclonal 
antibody 7E using direct ELISA. To measure serum marker of bone turnover, 
blood from mice was collected and centrifuged (2,000 rpm for 10 min at 
4°C), and serum was collected and stored at 80°C immediately. Serum 
CTX was determined using a CTX ELISA kit (Nordic Bioscience Diagnos-
tics). Serum osteocalcin, a biochemical parameter of bone formation, was 
measured using an osteocalcin ELISA kit (Nordic Bioscience Diagnostics).   
To analyze the enzyme activity of IL-20–treated OC CM, M-CSF–derived 
osteoclast precursors were cultured with 40 ng/ml of mouse M-CSF and 
100 ng/ml sRANKL (PeproTech) for 8 d to become mature multinucleated 
osteoclast.  Mature  osteoclasts  were  washed  twice  with  fresh  serum-free   
-MEM to make sure there was no residual sRANKL on the osteoclast.   
Mature osteoclast were treated with PBS or 100–200 ng/ml mouse IL-20 in 
-MEM containing 5% FBS for 20 h, and then the OC CM was collected for 
incubation with osteoblasts. Osteoblastic MC3T3-E1 cells were incubated 
with control OC CM, mIL-20–treated OC CM, or directly exposed to   
100–200 ng/ml mouse IL-20 for 20 h. The culture medium was then collected 
and sRANKL was determined using RANKL ELISA kit (PeproTech). 
Cathepsin G-specific inhibitor, N-tosyl-l-phenylalanine chloromethyl ke-
tone (TPCK; Sigma-Aldrich) was used to block the protease activity of ca-
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